News >

More Effective Therapies Needed in Uterine Sarcomas

Gina Columbus
Published: Friday, Aug 31, 2018

Richard Riedel, MD

Richard Riedel, MD

There is a limited number of effective therapies for patients with uterine sarcomas, notably due to trouble accruing for clinical trials, disappointing data, and the rarity of the disease, explained Richard Riedel, MD.

State of the Science Summit™ on Ovarian Cancer, Reidel discussed the presentation and standard management of uterine sarcomas, the potential role of immunotherapy and targeted agents, and the challenges he hopes to overcome in the landscape in the near future.

OncLive: What is the incidence of uterine sarcomas?

Reidel: Uterine sarcomas are extremely uncommon; they represent less than 5% of all uterine cancers. Even within that heading, there are a number of different subtypes, including adenosarcoma, endometrial stromal sarcomas of both low and high grade, perivascular epithelioid cell differentiation (PEC)omas, and undifferentiated uterine sarcomas and leiomyosarcomas. Despite the heading of uterine sarcomas, it really represents a number of different histologic subtypes with very clinical behaviors.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Show Me the Data™: Leveraging Evidence to Optimize Applications of PARP Inhibitor Strategies in Ovarian CancerJun 29, 20191.5
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x